[Acquired ichthyosis revealing hepatic and lymph node tuberculosis].
BACKGROUND
Acquired ichthyosis is an uncommon disease usually associated with different systemic diseases. Its characteristic clinical sign is symmetrical scaling of the skin. We report a case of acquired ichthyosis revealing hepatic and lymph node tuberculosis.


METHODS
A 41-year-old man was admitted to our hospital with weight loss and generalized acquired ichthyosis. Ultrasonography and computer tomography showed enlargement of abdominal lymph nodes. Lymph node and liver biopsy samples were taken during exploratory laparotomy and revealed multiple lymphoepitheliomas with Langhans-type giant cells and central caseous necrosis. The skin lesions resolved progressively after 5 months of antituberculous therapy.


CONCLUSIONS
Ichthyosis occurring in adulthood is often a sign of internal disease, especially malignant conditions. It has also been associated with autoimmune and infectious diseases, sarcoidosis and drugs. It is only rarely reported among patients with tuberculosis but it is possible that the ichthyosis in this case was due to weight loss and deterioration of the patient's general condition.
Rabhi
Monsef
M
Service de Médecine A, Hôpital Militaire d'Instruction Mohammed V, Rabat, Maroc. m_rabhi@menara.ma
Ennibi
Khalid
K
Berady
Sammy
S
Chaari
Jilali
J
Toloune
Farida
F
D000328:Adult; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D007057:Ichthyosis / Q000209:etiology*; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D007813:Laparotomy; D008099:Liver / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014386:Tuberculosis, Hepatic / Q000150:complications / Q000175:diagnosis* / Q000473:pathology; D014388:Tuberculosis, Lymph Node / Q000150:complications / Q000175:diagnosis* / Q000473:pathology
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin